COLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Collegium Pharmaceutical Inc (COLL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently oversold with a strong RSI signal, positive financial growth trends, and favorable analyst ratings. Despite the lack of recent news or significant trading trends, the company's consistent performance and growth potential make it a solid long-term investment.
The stock is oversold with an RSI of 7.72, indicating a potential rebound. The MACD histogram is negative and expanding, suggesting bearish momentum, but the stock is trading near its S2 support level of 36.273, which could act as a strong buying zone. Moving averages are converging, signaling potential price stabilization.
Strong financial performance in Q4 2025 with revenue up 12.92% YoY, net income up 35.31% YoY, and EPS up 28.57% YoY.
Positive analyst sentiment with multiple Buy and Overweight ratings and price targets ranging from $55 to $
Oversold RSI indicating potential for price recovery.
MACD indicates bearish momentum.
Lack of recent news or significant trading trends from hedge funds or insiders.
Post-market price decline of -0.08%, though minimal.
In Q4 2025, Collegium Pharmaceutical reported strong financial growth: Revenue increased by 12.92% YoY to $205.45M, net income rose by 35.31% YoY to $16.96M, EPS improved by 28.57% YoY to $0.45, and gross margin increased by 15.68% YoY to 62.49%.
Analysts maintain a positive outlook on COLL with multiple Buy and Overweight ratings. Recent price target updates range from $55 to $60, reflecting confidence in the company's growth trajectory, particularly for its Jornay product and pain portfolio.
